Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Cash & Current Investments: 2019-2024

Historic Cash & Current Investments for Kymera Therapeutics (KYMR) over the last 6 years, with Dec 2024 value amounting to $488.7 million.

  • Kymera Therapeutics' Cash & Current Investments fell 8.05% to $505.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 billion, marking a year-over-year increase of 21.15%. This contributed to the annual value of $488.7 million for FY2024, which is 30.37% up from last year.
  • Per Kymera Therapeutics' latest filing, its Cash & Current Investments stood at $488.7 million for FY2024, which was up 30.37% from $374.9 million recorded in FY2023.
  • In the past 5 years, Kymera Therapeutics' Cash & Current Investments ranged from a high of $488.7 million in FY2024 and a low of $296.2 million during FY2020.
  • Its 3-year average for Cash & Current Investments is $423.6 million, with a median of $407.2 million in 2022.
  • In the last 5 years, Kymera Therapeutics' Cash & Current Investments soared by 222.11% in 2020 and then dropped by 7.97% in 2022.
  • Yearly analysis of 5 years shows Kymera Therapeutics' Cash & Current Investments stood at $296.2 million in 2020, then skyrocketed by 49.36% to $442.4 million in 2021, then dropped by 7.97% to $407.2 million in 2022, then declined by 7.93% to $374.9 million in 2023, then surged by 30.37% to $488.7 million in 2024.